Resistance to platinum and taxane based chemotherapy remains a major clinical impediment to effective management of epithelial ovarian cancer (EOC). To gain insights into resistance mechanisms, we compared gene and confirmed expression patterns of novel EOC cell lines selected for paclitaxel and carboplatin resistance. Here we report that resistance can be conferred 
Introduction
The Polo-like kinases (Plks) are a family of serine-threonine kinases invovled in cell cycle regulation and cellular response to stresses e.g. DNA damage. Plk1 is the best characterised and positively regulates progression through G2 (1) . Polo-like kinase 2/Snk (Plk2) and Polo-like kinase 3 Plk3/Fnk/Prk (Plk3) were identified as immediate-early transcripts in mouse fibroblasts (2 -4) , whilst Plk4 (SAK) functions in centriole biogenesis (5 -9) . Plk1 is over-expressed in various cancers supporting treatment strategies designed to target it (10, 11) . Plk2 has a role in development and is required for centriole duplication (12, 13) , although Plk2 -/-mice are viable (14) . Plk2 induces apoptosis in Burkitt's lymphoma (BL) cells (15) and expression is directly induced by wild-type p53 (16) . Under normal physiological conditions, Plk2 protein is subject to proteosomal degradation via the ubiquitin ligase hVPS18 (17) . Methylation-dependent transcriptional silencing of Plk2 is common in BL (15) . Transcriptional silencing of many genes is described for EOC (18) .
EOC is often a chronic disease, characterized by long-term responsiveness to chemotherapy. Cisplatin and carboplatin are key agents in EOC management and cancers may retain sensitivity to these drugs for prolonged periods and sometimes, even after clinical relapse. Paclitaxel (Taxol®) and docetaxel (Taxotere®) are frequently used in combination with platinum for treating EOC. There is emerging evidence that epigenetic changes contribute significantly to acquired chemotherapy resistance (19 -21) . We show herein that Plk2 is a determinant of sensitivity to paclitaxel and platinum.
5 ThermoScientific, UK) according to the manufacturer's protocol. Following 72h of silencing, SKOV-3 cells were sub-cultured into T25 2 tissue culture flasks at approximately 30-50% confluence and exposed to paclitaxel (10nM) or carboplatin (100μM) (both used at approximately twice the IC 50 dose) for a period of 48h, then harvested and subjected to the annexin assay.
Clinical Samples
Samples of EOC were obtained from the Tissue Bank of the Charité Hospital, Berlin, Germany. Tissue obtained at initial debulking surgery and at first relapse (obtained with informed consent and local ethical committee approval) were collected as snap-frozen biopsies at surgery. Serum was collected at the time of diagnosis and relapse and stored at -80 o C. Genomic DNA was obtained from tissues using proteinase K/ phenol and from serum using the Qiagen system. Cases were predominantly serous adenocarcinomas (n= 43), but also included endometrioid carcinomas (n= 5), mucinous (n=1), clear cell (n=1), mixed histology (n=2) and 2 unclassified cases (supplementary Table 2 ). Post-operative chemotherapy comprised carboplatin and paclitaxel for all patients, given on either a 21 day (q21) or 7 day (q7) schedule. In some cases Gemcitabine was added. Response was assessed by standard criteria including clinical examination, serum CA125 and computerized tomographic (CT) imaging.
mRNA analysis
Analysis of Plk2 expression by RT-PCR and qPCR was as described previously (15) .
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Methylation analysis
Genomic DNA was purified from cell pellets by proteinase K digestion and from serum using a commercially available system (Qiagen). For methylation analysis, genomic DNA (1μg) was modified by sodium bisulphite as described previously (15) . The location of primers for bisulphite sequencing and MSP is shown in Supplementary Material, Figure 1. qMSP of the Plk2 CpG island was carried out using primer pair 4. PCR was performed in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) using SyBRGreen (Qiagen).
Western blotting
Cell pellets were prepared from attached and floating cell populations, then subjected to osmotic rupture in hypotonic detergent based buffer (1mM PMSF, NaVO4, aprotinin and leupeptin as protease inhibitors, 150mM NaCl, in 50mM Tris buffer, 0.2% SDS, 1% NP-40, pH 7.5) and 40-50μg of protein/sample electrophoresed on SDS-PAGE gels. Membranes were incubated overnight at 4 0 C with primary antibody-Plk2 antibody (sc-25421, H-90 rabbit polyclonal antibody, Insight Biotechnology, London, UK) or Plk1,3 and 4 (AbCam, Cambridge, UK). In some experiments, the anti-Plk2 antibody used was as described previously (13, 15) . Following the probing of each membrane with the primary antibody of choice, the membrane was stripped and re-probed using a GAPDH, PCNA or actin antibody as loading control. Antibodies against Plk1, Plk3 and Plk4 were from AbCam. 
Cytotoxicity assays
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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A2780 and SKOV-3 parental and resistant cells for cytotoxicity testing were seeded into 96-well plates at a density of 3-4 x 10 4 cells/ml to allow approximately 3-doublings (approximately 10-20-fold increase in control cell number) for the duration of the drug exposure. Cells were allowed to attach and equilibrate for 24h, then treated with various concentrations of drug over 2-3 log orders of concentration. Results were not materially affected by initial plating densities. Drugs were diluted in tissue culture medium containing 10% FCS. Control cell wells were treated with drug-free tissue culture medium. Drugtreated cells were then returned to the incubator for a period of 72h. Cell viability was determined by addition of 0.1mg MTT (thiazoyl blue tetrazolium bromide) to each well for 4h at 37 o C. Wells were aspirated to remove the medium, the resulting formazan crystals solubilized in 200μl DMSO and the absorbance read at 570nM. The absorbance of the formazan product obtained for drug-treated cells was calculated as a fraction of that for the untreated control wells. Growth curves were constructed using PRISM software and results expressed as IC 50 values i.e. dose of drug causing a 50% reduction in cell viability.
Annexin V assay for assessment of apoptosis:
The effect of drugs on cell cycle distribution was assessed by flow cytometry as described previously (15) . Cell death was assessed by measurement of apoptosis using Annexin V. was assessed using a collection of 10,000 events. All analyses were carried out in triplicate.
Statistical analysis
Statistical analysis was carried out using SPSS (version 14) and MiniTab programs. Tissue and serum methylation results were assessed in the groups of responders and nonresponders in terms of the utility of DNA methylation as a potential marker of chemoresponsiveness. 
Results
Ovarian
Drug resistance is associated with loss of G2M checkpoint
Using annexin V staining and flow cytometry, we asked whether resistance to paclitaxel was associated with changes in drug-induced apoptosis and/or cell cycle distribution. In 
Methylation and expression of Plk2 vary quantitatively with drug resistance
We analysed expression and methylation of Plk2. in our panel of paclitaxel resistant variants of A2780. Bisulphite sequencing showed a progressive, quantitative increase in methylation with increasing drug resistance ( Figure 5A ). qMSP analysis confirmed that methylation increased with increasing paclitaxel resistance ( Figure 5B ). Expression of Plk2 mRNA ( Figure 5C ) and protein ( Figure 5D ) decreased with increasing paclitaxel resistance, consistent with changes in CpG methylation.
Paclitaxel resistance correlates with epigenetic status of the Plk2 CpG island
We next tested the stability of the drug resistant phenotype. Clones of the A2780 paclitaxelresistant cell line panel with increasing levels of primary resistance to paclitaxel, were transferred to drug-free medium and grown continuously in the absence of paclitaxel. After 
Plk2 expression modulates cytotoxicity of carboplatin and paclitaxel
We used plasmid-mediated inhibitory RNA (RNAi) to stably down-regulate Plk2 in the drug sensitive A2780 parent cell line. Knock-down was confirmed by RT-PCR ("KD" in Figure   7A ). Clonal cell lines with "knocked-down" expression of Plk2 (A2780KD) were challenged with a cytotoxic concentration of paclitaxel ( Figure 7B ). G2M block and increase in the sub-G1 population were greatly reduced in the knocked-down cells ( Figure 7B ). To exclude socalled "off-target" effects, A2780 cell lines with knocked-down Plk2 (A2780KD) were retransfected with a Plk2 expression plasmid (A2780KD + KI). The effect of Plk2 reexpression was increased paclitaxel-induced G2M blocked and sub-G1 populations, relative to the A2780KD cells ( Figure 7B ). Next, we ectopically expressed Plk2 in A2780TaxR 354 cells which have undetectable levels of endogenous Plk2. Flow cytometry revealed that in The silenced cells were exposed to paclitaxel and carboplatin for 48h. There was a reproducible reduction in apoptosis induced by both paclitaxel and carboplatin in cells silenced for Plk2 expression compared to control cells ( Figure 7E ).
Plk2 is a candidate predictor of chemotherapy resistance in EOC
We used quantitative MSP (qMSP) to analyse methylation in the Plk2 CpG island in a test 
Discussion
We show that Plk2 is a determinant of cellular sensitivity to paclitaxel and carboplatin and via a mechanism of methylation-dependent transcriptional silencing, Plk2 is associated with drug resistance. Paclitaxel resistance in A2780 cell lines was associated with reduction or complete loss of the drug-induced G2M checkpoint and reduced apoptosis.
Similarly, in paclitaxel or carboplatin resistant SKOV-3 cells, there was reduced apoptosis relative to drug-sensitive parental cells. Importantly, in A2780 and SKOV-3 cell lines with acquired resistance to paclitaxel, there was significantly reduced apoptosis when challenged with platinum compounds. Moreover, carboplatin-resistant SKOV-3 cells exhibited reduced apoptosis when exposed to paclitaxel.
Plk2 has both G2M checkpoint (16) and pro-apoptotic (15) 
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reversible when cells were allowed a drug-free "holiday". In such cell lines, with reacquired drug sensitivity, expression of Plk2 increased with increasing drug sensitivity. Our results are compatible with studies showing that decreased sensitivity to paclitaxel is associated with compromised checkpoint function or spindle assembly (24) (25) (26) . Our data are also consistent with micro-array analyses of platinum-resistant cell lines in which Plk2 is downregulated (21; 27). Together, these results afford further support for the candidacy of Plk2 as a determinant of chemotherapy sensitivity and for a predominantly epigenetic basis for acquired drug resistance (28) . Our data also imply that Plk2 expression and Plk2-associated kinase activity may be required, at least in some cell types, for sensitivity to chemotherapy. This is supported by a recent study in chronic lymphocytic leukaemia in which failure of Plk2 upregulation was associated with chemotherapy resistance (29) . resistant MCF-7 cells, supports a general model of acquired drug resistance in which opposing and ongoing hypo-and hypermethylation in multiple genes is a major mechanism driving the process of drug resistance (31) . In initial clinical studies we show that cases of EOC with Plk2 methylation at diagnosis were at significantly increased risk of early clinical relapse with a less favourable response to post-operative chemotherapy than cases lacking methylation. Also, methylated Plk2 DNA in serum was more common at clinical relapse than at initial diagnosis. Our results imply that analysis of Plk2 methylation may have utility as a biomarker of both disease activity and of chemo-sensitivity in EOC. In the context of our results, Plk2 has been identified as a significantly down-regulated gene in chemotherapy-resistant primary ovarian carcinomas, affording independent validation of our hypothesis for it being a determinant of chemotherapy sensitivity and candidate biomarker in EOC (32) . An important feature of the taxane resistant cell line models we use in the current study is their cross-resistance with platinum agents. In support of this, previous reports in the literature cite decreased platinum sensitivity with cross resistance to chemotherapeutic agents such as taxanes in EOC cell lines (33) . Clinically, a proportion of EOC patients show platinum-taxane non-cross resistance (34) . Both our cell line panel data and our EOC patient cohort used in the present study are representative of platinum and taxane cross-resistance.
We previously reported that Plk2 is subject to transcriptional down-regulation in B lymphomas and expression profiling has shown that Plk2 down-regulation is a predictor of poor clinical outcome in B lymphomas (35) . Our data are in support of clinical trials of epigenetic therapies in EOC patients, and other cancer patients (36) and suggest that detection of methylated Plk2 DNA warrants independent evaluation in larger clinical series 
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as a candidate predictor of response of EOC patients to chemotherapy and as a serum biomarker of drug-resistant clinical relapse.
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A2780TaxR 354 were exposed to paclitaxel then subjected to flow cytometry. C: SKOV-3 parent cells, SKOV-3TaxR and SKOV-3CR were exposed to paclitaxel, then subjected to flow cytometry (data shown are representative of repeat experiments). Figure 3 , the anti-Plk2 antibody used for western blotting detects a doublet, the upper band of which is Plk2 (arrowed).
PCNA is shown as a loading control. 
